KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Debt (2021 - 2025)

Pacira BioSciences has reported Non-Current Debt over the past 9 years, most recently at $372.2 million for Q4 2025.

  • Quarterly results put Non-Current Debt at $372.2 million for Q4 2025, down 2.96% from a year ago — trailing twelve months through Dec 2025 was $372.2 million (down 2.96% YoY), and the annual figure for FY2025 was $372.2 million, down 2.96%.
  • Non-Current Debt for Q4 2025 was $372.2 million at Pacira BioSciences, down from $376.7 million in the prior quarter.
  • Over the last five years, Non-Current Debt for PCRX hit a ceiling of $383.5 million in Q4 2024 and a floor of $97.8 million in Q2 2025.
  • Median Non-Current Debt over the past 5 years was $137.5 million (2023), compared with a mean of $218.1 million.
  • Biggest five-year swings in Non-Current Debt: tumbled 61.93% in 2023 and later skyrocketed 252.0% in 2025.
  • Pacira BioSciences' Non-Current Debt stood at $335.3 million in 2021, then fell by 25.12% to $251.1 million in 2022, then plummeted by 54.11% to $115.2 million in 2023, then soared by 232.93% to $383.5 million in 2024, then fell by 2.96% to $372.2 million in 2025.
  • The last three reported values for Non-Current Debt were $372.2 million (Q4 2025), $376.7 million (Q3 2025), and $97.8 million (Q2 2025) per Business Quant data.